Loading
Life sciences · Journal article
Science Translational Medicine · September 23, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Small cell lung cancer (SCLC) represents the most lethal subtype of lung carcinoma. Platinum-based agents, such as cisplatin and carboplatin, remain the cornerstone of first-line therapy for patients with SCLC, whether administered as chemotherapy alone or in combination with immunotherapy. However, patients frequently develop platinum resistance within a short time frame, leading to therapeutic failure. The molecular mechanisms underlying platinum resistance in SCLC require further investigation, given that effective intervention strategies remain elusive. Through multiomic analysis integrating transcriptomic data from cisplatin-resistant PDX tissues and the IMpower133 SCLC cohort study and translatomic data from SCLC cells, we identified a platinum resistance–associated noncanonical open reading frame derived from MIR7 - 3HG. This noncanonical ORF encodes an unannotated 128–amino acid protein, designated SCRMP (SCLC cisplatin resistance–associated microprotein). SCRMP was up-regulated in cisplatin-resistant SCLC tissues and cell lines, and its elevated expression strongly correlated with impaired platinum response and unfavorable survival outcomes in patients. CRISPR-Cas9–mediated SCRMP knockout restored cisplatin sensitivity and promoted apoptosis in SCLC cells, platinum-resistant patient–derived organoids in vitro, and patient-derived xenografts in vivo. Mechanistically, SCRMP potentiated platinum resistance by mediating SUMOylation and nuclear translocation of CSNK2B, which stabilized the RBBP4-p300 complex. This stabilization activated transcription of RAD51C and associated DNA damage repair genes through histone acetylation, ultimately promoting therapeutic resistance. Our study systematically elucidates the biological function of SCRMP in SCLC platinum resistance and delineates its specific molecular mechanism in regulating DNA damage repair, thereby providing theoretical foundations and potential intervention strategies for overcoming platinum resistance in SCLC.